Prospective observational study of patient-reported outcomes for azithromycin versus usual care in the treatment of bacterial acute exacerbation of chronic bronchitis

Clinical Therapeutics

Volumn 27, Issue 6, 2005, Pages 926-939

  Milstone, Aaron ^a   Patsimas, John ^b   Farzan, David ^c   Castaldo, Richard ^d   Singh, Harmeet ^e   Feurer, Irene ^a   Harnett, James ^f   Luke, David R ^f  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b Family Practice Center   (United States)

^c Lawrence General Hospital   (United States)

^d Kenmore Mercy Hospital   (United States)

^e Pfizer Inc ^*

^f PFIZER INC   (United States)

Author keywords

Antibacterials; Azithromycin; Chronic bronchitis; SGRQ

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CIPROFLOXACIN; CLARITHROMYCIN; GATIFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; CHRONIC BRONCHITIS; CLINICAL FEATURE; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE EXACERBATION; FEMALE; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT COMPLIANCE; PROSPECTIVE STUDY; QUALITY OF LIFE; QUESTIONNAIRE; SCORING SYSTEM; TREATMENT OUTCOME;

EID: 27744484688     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2005.06.001     Document Type: Article

References (34)

1. Halpern MT, Higashi MK, Bakst AW, Schmier JK. The economic impact of acute exacerbations of chronic bronchitis in the United States and Canada: A literature review. J Manag Care Pharm. 2003;9:353-359.
2. Bronchitis. National Center for Health Statistics Web site. Available at: http://www.cdc.gov/nchs/fastats/brnchtis.htm. Accessed November 2004.
3. Celli BR, MacNee W, for the ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: A summary of the ATS/ERS position paper, Eur Respir J. 2004;23:932-946.
4. Guay D. Short-course antimicrobial therapy of respiratory tract infections. Drugs. 2003;63:2169-2184.
5. Macfarlane J, Holmes W, Gard P, et al. Prospective study of the incidence, aetiology and outcome of adult lower respiratory tract illness in the community. Thorax. 2001; 56:109-114.
6. Steinman MA, Landefeld CS, Gonzales R. Predictors of broad-spectrum antibiotic prescribing for acute respiratory tract infections in adult primary care. JAMA. 2003;289:719-725.
7. McIsaac WJ, To T. Antibiotics for lower respiratory tract infections. Still too frequently prescribed? Can Fam Physician. 2004;50:569-575.
8. Sanford Guide to Antimicrobial Therapy 2003. Hyde Park, Vt: Antimicrobial Therapy Inc; 2003.
9. File TM Jr, Garau J, Blasi F, et al. Guidelines for empirical antimicrobial prescribing in community-acquired pneumonia. Chest. 2004;125:1888-1901.
10. Balter MS, La Forge J, Low DE, et al, for the Canadian Thoracic Society and the Canadian Infectious Disease Society. Canadian guidelines for the management of acute exacerbations of chronic bronchitis. Can Respir J. 2003; 10(Suppl B):3B-32B.
11. McCaig LF, Besser RE, Hughes JM. Antimicrobial drug prescription in ambulatory care settings, United States, 1992-2000 [published correction appears in Emerg Infect Dis. 2003;9:609]. Emerg Infect Dis. 2003;9:432-437.
12. Gonzales R, Steiner JF, Sande MA. Antibiotic prescribing for adults with colds, upper respiratory tract infections, and bronchitis by ambulatory care physicians. JAMA. 1997;278:901-904.
13. Drugs@FDA Web site. Available at: http://www.accessdata. fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction-Search. Overview&DrugName-ZITHROMAX. AccessedJune 2005.
14. Swanson RN, Lainez-Ventosilla A, De Salvo MC, et al. 3-Day azithromycin 500 mg qd versus 10-day clarithromycin 500 mg bid for acute exacerbation of chronic bronchitis in adults. Poster presented at: 98th International Annual Meeting of the American Thoracic Society; May 19-22, 2002; Atlanta, Ga.
15. Contopoulos-Ioannidis DG, Ioannidis JP, Chew P, Lau J. Meta-analysis of randomized controlled trials on the comparative efficacy and safety of azithromycin against other antibiotics for lower respiratory tract infections. J Antimcrob Chemother. 2001;48:691-703.
16. Perez-Gorricho B, Ripoll M, for the PACE Study Group. Does short-course antibiotic therapy better meet patient expectations? Int J Antimicrob Agents. 2003;21:222-228.
17. Sclar DA, Tartaglione TA, Fine MJ. Overview of issues related to medical compliance with implications for the outpatient management of infectious diseases. Infect Agents Dis. 1994;3:266-273.
18. Spencer S, Jones PW, for the GLOBE Study Group. Time course of recovery of health status following an infective exacerbation of chronic bronchitis. Thorax. 2003;58:589-593.
19. Jones PW, Wilson R, Duprat-Lomon I, et al. Health status changes following antibiotic treatment of an acute exacerbation of chronic bronchitis (AECB) reduce the risk of AECB recurrence in COPD-The MOSAIC Study. Poster presented at: 100th International Meeting of the American Thoracic Society; May 21-26, 2004; Orlando, Fla.
20. Torrance C, Walker V, Grossman R, et al. Economic evaluation of ciprofloxacin compared with usual antibacterial care for the treatment of acute exacerbations of chronic bronchitis in patients followed for 1 year. Pharmaco-Economics. 1999;16:499-520.
21. Grossman R, Mukherjee J, Vaughan D, et al. A 1-year community-based health economic study of ciprofloxacin vs usual antibiotic treatment in acute exacerbations of chronic bronchitis: The Canadian Ciprofloxacin Health Economic Study Group. Chest. 1998;113:131-141.
22. Anthonisen NR, Manfred J, Warren CP, et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med. 1987;106:196-204.
23. Medical Research Council. Committee on the Aetiology of Chronic Bronchitis: Standardised questionnaire on respiratory symptoms. BMJ. 1960;2:1665.
24. Borg GA. Psychophysical bases of perceived exertion. Med Sci Sports Exerc. 1982;14:377-381.
25. Elliott MW, Adams L, Cockcroft A, et al. The language of breathlessness. Use of verbal descriptors by patients with cardiopulmonary disease. Am Rev Respir Dis. 1991;144:826-832.
26. Jones PW, Quirk FH, Baveystock CM. The St George's Respiratory Questionnaire. Respir Med. 1991;85 (Suppl B):25-31.
27. Jones PW, Quirk FH, Baveystock CM, Littlejohns P, for the St. George's Respiratory Questionnaire. A self-complete measure of health status for chronic airflow limitation. Am Rev Respir Dis. 1992;145:1321-1327.
28. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30:473-483.
29. Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: The remarkable universality of half a standard deviation. Med Care. 2003;41: 582-592.
30. Kesten S, Chapman KR, Physician perceptions and management of COPD. Chest. 1993;104:254-258.
31. Wilson R, Schentag JJ, Ball P, Mandell L, for the 068 Study Group. A comparison of gemifloxacin and clarithromycin in acute exacerbations of chronic bronchitis and long-term clinical outcomes. Clin Ther. 2002;24:639-652.
32. Chodosh S, Schreurs A, Siami G, et al, for the Bronchitis Study Group. Efficacy of oral ciprofloxacin vs. clarithromycin for treatment of acute bacterial exacerbations of chronic bronchitis. Clin Infect Dis. 1998;27: 730-738.
33. Linder JA, Sim I. Antibiotic treatment of acute bronchitis in smokers: A systematic review. J Gen Intern Med. 2002;17:230-234.
34. Barr JT, Schumacher GE, Freeman S, et al. American translation, modification, and validation of the St. George's Respiratory Questionnaire. Clin Ther. 2000;22:1121-1145.